Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

17.23 -0.35 (-2.02%)
Delayed Quote Updated: 2:55 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
What This Immunome Sale Means a Day Before a Big FDA Milestone ↗
Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More ↗
This biotech innovator in antibody therapeutics reported a notable insider sale amid a year of dramatic share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway. 
Via The Motley Fool
News headline image
Where Immunome Stands With Analysts ↗
 
Via Benzinga
News headline image
Where Immunome Stands With Analysts ↗
 
Via Benzinga
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’ ↗
Via Stocktwits
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies. 
Via The Motley Fool
News headline image
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Analyst Expectations For Immunome's Future ↗
 
Via Benzinga
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Immunome Stock Surged Today ↗
The oncology specialist's targeted therapies could improve thousands of lives. 
Via The Motley Fool
News headline image
Which stocks are gapping on Monday? ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Why Is IMNM Stock Rising Today? ↗
Immunome stock is on track to open at its highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type... 
Via Stocktwits
News headline image
This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday ↗
 
Via Benzinga
News headline image
This GATX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
This Netgear Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday ↗
 
Via Benzinga
News headline image
Immunome (IMNM) Q2 Revenue Surges 382% ↗
Via The Motley Fool
News headline image
These stocks are moving in today's after hours session ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
3 Small-Cap Stocks With Big Growth Potential
Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space. 
Via MarketBeat
Topics Economy
News headline image
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Immunome Stock Sees RS Rating Jump To 91 ↗
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91. 
Via Investor's Business Daily
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.